BetterInvesting™ Magazine Update on Stride Inc. (NYSE: LRN) and Amgen Inc. (NASDAQ: AMGN)PRNewsWire • 05/28/25
The Smartest High-Yielding Dividend Stocks in the Nasdaq Composite Index to Buy With $1,500 Right NowThe Motley Fool • 05/24/25
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a ResultThe Motley Fool • 05/24/25
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)Seeking Alpha • 05/21/25
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes LingerZacks Investment Research • 05/21/25
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?Zacks Investment Research • 05/19/25
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A ReversalBenzinga • 05/15/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug CostsZacks Investment Research • 05/12/25
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price ReformInvestors Business Daily • 05/12/25
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United KingdomBusiness Wire • 05/07/25
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales GrowthZacks Investment Research • 05/05/25